Skip to main content
Professor Timothy Walsh

Professor Timothy Walsh


School of Medicine

+44 (0)29 2074 4725
UHW Main Building


Timothy Walsh is currently Professor of Medical Microbiology and Antibiotic Resistance at Cardiff University, Cardiff, Wales, and leads an active research in antibiotic resistance and evaluating pipeline antibiotics. Previously, he was a Reader in Medical Microbiology at the University of Bristol following several postdoctoral research positions in London, UK.  Prof. Walsh is a member of the Australian Society of Microbiology, Society for General Microbiology (UK), British Society of Antimicrobial Chemotherapy, American Society of Microbiology and European Society of Clinical Microbiology and Infectious Diseases.  Prof. Walsh’s research is focused on assessing the burden of AMR in low-middle income countries, particularly in the most vulnerable populations. He has published/presented over 600 papers in particular on the characterization of AMR mechanisms in Gram-negative bacteria, and publishes in journals such as Clinical Microbiological Reviews, Microbiology and Molecular Biology Reviews, Clinical Infectious Diseases, Nature, Nature Microbiology, Nature Communications, Lancet and Lancet Infectious Diseases. His research has been funded by the, MRC, EC, GCRF, UKRI, Wellcome Trust, European Bank, BBSRC, and the Gates Foundation. After obtaining a BSc in Applied Laboratory Science and a Post Graduate Diploma of Immunology/Microbiology at the University of Tasmania in Australia, Prof. Walsh read Molecular Microbiology at the University of Bristol under the tutelage of Prof. Peter Bennett, and completed his PhD in 1995.


I have been studying AMR mechanisms for over 20 years, published over 300 papers and publish regularly in Nature and Lancet journals. I am PI of BARNARDS, the lead Gates Foundation project on clinical AMR, examining the burden of neonatal sepsis in Pakistan, India, Bangladesh, Rwanda, South Africa, Nigeria (Abuja and Kano) and Ethiopia. This project thus far has enrolled 36,000 mothers and analysed over 2000 sepsis cases.

I am also PI of DETER-XDR-CHINA and the recently funded DX-China-HUB, a study examining the spread and burden of AMR in public health sectors and hospitals in 30 provinces in China. I hold an honorary Chair at the Chinese Agricultural University and I am an AMR advisor to the Chinese MoH and was involved in the decision for the Chinese government to ban the use of colistin as a growth-promoter in farming. I am also PI of CUT-SEC, a ‘one-health” project in China and Thailand.

I am also PI of the MRC grant to establish an AMR surveillance system throughout Vietnam in collaboration with NIHE and the Wellcome Trust Center in Hanoi. In addition to BARNARDS, I also have AMR studies in Karachi and Peshawar, Niger (Clean Kids Study) and support MSF Microbiology/AMR lab in Jordan. My lab has provided molecular support for the Russian Federation Reference Laboratory in AMR surveillance that covers Russia, Belarus and Kazakhstan. I also have clinical studies examining the burden of AMR in the community and hospitals San Paolo (Brazil), Phitsanulok (Thailand) and Tanta (Egypt) and Dhaka (Bangladesh). 

I have also been appointed as a lead microbiologist to the Fleming Fund Expert Advisory Panel – a £265M AMR capacity building program with special interest in Nigeria, Pakistan and Bangladesh.  He is also advisor to the WHO, Chinese CDC and MSF.